Therapeutic mRNA delivery to leukocytes.

In the past few years mRNA molecules have become an attractive class of new drugs with numerous opportunities. mRNA therapeutics holds great potential for the treatment of a variety of diseases and is an emerging field both in academia and in the pharma industry. Among the various mRNA-based therapeutic approaches, immunotherapy is one of the pioneering and most advanced therapy to date. Immune cells manipulation using mRNA is commonly used for vaccination purposes, but its potential is much broader. In this review, we discuss the promise of mRNA delivery to leukocytes. We aim to provide an overview of the main progress in this field, as well as the challenges in expanding the scope of mRNA therapy for different therapeutic applications. We also discuss the main technological developments for overcoming mRNA therapy limitations, including mRNA rational design and delivery platforms.

[1]  Dan Peer,et al.  The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. , 2010, Biomaterials.

[2]  R. Langer,et al.  mRNA vaccine delivery using lipid nanoparticles. , 2016, Therapeutic delivery.

[3]  D. Weissman,et al.  Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Ryan Cross,et al.  Can mRNA disrupt the drug industry , 2018 .

[5]  E. Gilboa,et al.  An RNA toolbox for cancer immunotherapy , 2018, Nature Reviews Drug Discovery.

[6]  C. Lukacs,et al.  Systemic messenger RNA as an etiological treatment for acute intermittent porphyria , 2018, Nature Medicine.

[7]  J. Hauber,et al.  mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5 , 2015, Nucleic acids research.

[8]  Jonathan L. Kirschman,et al.  Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection , 2018, Nature Communications.

[9]  Mohammad Ariful Islam,et al.  Biomaterials for mRNA delivery. , 2015, Biomaterials science.

[10]  D. Weissman,et al.  mRNA vaccines — a new era in vaccinology , 2018, Nature Reviews Drug Discovery.

[11]  B. Sacchetti,et al.  CAR-T cells: the long and winding road to solid tumors , 2018, Cell Death & Disease.

[12]  T. Schlake,et al.  A novel, disruptive vaccination technology , 2013, Human vaccines & immunotherapeutics.

[13]  H. Döhner,et al.  Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids , 2007, Leukemia.

[14]  T. Schlake,et al.  mRNA as novel technology for passive immunotherapy , 2018, Cellular and Molecular Life Sciences.

[15]  Kimberly J. Hassett,et al.  Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  Kimberly J. Hassett,et al.  Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  L. Maquat,et al.  Regulation of cytoplasmic mRNA decay , 2012, Nature Reviews Genetics.

[18]  Kerstin F. Gerer,et al.  RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma , 2017, BMC Cancer.

[19]  Amos Etzioni,et al.  Leukocyte adhesion deficiencies , 2012, Annals of the New York Academy of Sciences.

[20]  Antigens , 2020, Encyclopedia of Behavioral Medicine.

[21]  H. Abken,et al.  Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response , 2010, Gene Therapy.

[22]  G. Fitzgerald,et al.  'I. , 2019, Australian journal of primary health.

[23]  D. Peer,et al.  Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint. , 2017, Seminars in immunology.

[24]  G. Bensi,et al.  Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. , 2017, Vaccine.

[25]  M. Roberti,et al.  Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients , 2013, Innate immunity.

[26]  Daniel G. Anderson,et al.  Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs. , 2015, Nano letters.

[27]  Robert Langer,et al.  Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. , 2017, Nano letters.

[28]  E. Alici,et al.  Natural killer cell‐based immunotherapy in cancer: current insights and future prospects , 2009, Journal of internal medicine.

[29]  Thomas Krucker,et al.  Nonviral delivery of self-amplifying RNA vaccines , 2012, Proceedings of the National Academy of Sciences.

[30]  Yong-Hee Kim,et al.  Mononuclear phagocytes as a target, not a barrier, for drug delivery , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[31]  J. Cooke,et al.  Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA , 2015, Cell Discovery.

[32]  Katayoun Rezvani,et al.  Engineering Natural Killer Cells for Cancer Immunotherapy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  G. Lenzen,et al.  Induction of virus‐specific cytotoxic T lymphocytes in vivo by liposome‐entrapped mRNA , 1993, European journal of immunology.

[34]  B. Levine,et al.  Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. , 2010, Cancer research.

[35]  Sandro Matosevic,et al.  Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies , 2018, Journal of immunology research.

[36]  U. Şahin,et al.  Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond , 2015, Wiley interdisciplinary reviews. RNA.

[37]  Wei-Ting Hwang,et al.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.

[38]  Daniel G. Anderson,et al.  Advances in the delivery of RNA therapeutics: from concept to clinical reality , 2017, Genome Medicine.

[39]  Catherine J. Wu,et al.  Towards personalized, tumour-specific, therapeutic vaccines for cancer , 2017, Nature Reviews Immunology.

[40]  S. Smedt,et al.  Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment , 2014 .

[41]  D. Peer,et al.  RNA nanomedicines: the next generation drugs? , 2016, Current opinion in biotechnology.

[42]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  Stefaan C De Smedt,et al.  Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger. , 2016, Drug discovery today.

[44]  Dan Peer,et al.  Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes , 2018, Nature Communications.

[45]  Wenxin Wang,et al.  A new developing class of gene delivery: messenger RNA-based therapeutics. , 2017, Biomaterials science.

[46]  Aristidis Tsatsakis,et al.  Protein bio-corona: critical issue in immune nanotoxicology , 2016, Archives of Toxicology.

[47]  Dan Peer,et al.  Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions. , 2017, ACS nano.

[48]  F. Rottman,et al.  Biosynthesis and Functions of Modified Nucleosides in Eukaryotic mRNA , 1998 .

[49]  Chao Shan,et al.  Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease , 2017, Cell.

[50]  L. Defrancesco.  The 'anti-hype' vaccine , 2017, Nature Biotechnology.

[51]  W. Lim,et al.  The Principles of Engineering Immune Cells to Treat Cancer , 2017, Cell.

[52]  M. Czuczman,et al.  Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice , 2014, Cancer Immunology Research.

[53]  Dan Peer,et al.  Toxicity profiling of several common RNAi-based nanomedicines: a comparative study , 2013, Drug Delivery and Translational Research.

[54]  K. Karikó,et al.  The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[55]  H. Rammensee,et al.  In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies , 2000 .

[56]  T. Schlake,et al.  Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[57]  C. Nabhan,et al.  Chronic lymphocytic leukemia: a clinical review. , 2014, JAMA.

[58]  I. Verma,et al.  Systemic delivery of factor IX messenger RNA for protein replacement therapy , 2017, Proceedings of the National Academy of Sciences.

[59]  D. Torigian,et al.  Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.

[60]  S. Rosenberg,et al.  Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[61]  D. Weissman,et al.  Zika virus protection by a single low dose nucleoside modified mRNA vaccination , 2017, Nature.

[62]  Özlem Türeci,et al.  mRNA-based therapeutics — developing a new class of drugs , 2014, Nature Reviews Drug Discovery.

[63]  K. G. Rajeev,et al.  Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[64]  Özlem Türeci,et al.  Elimination of large tumors in mice by mRNA-encoded bispecific antibodies , 2017, Nature Medicine.

[65]  Robert Altenloh.  From a Novel , 1953 .

[66]  F. Bertucci,et al.  Peripheral Blood NK Cells from Breast Cancer Patients Are Tumor-Induced Composite Subsets , 2013, The Journal of Immunology.

[67]  D. Campana,et al.  A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. , 2012, Cytotherapy.

[68]  W. Wels,et al.  Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens , 2012, Leukemia & lymphoma.

[69]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[70]  Anand Ramanathana,et al.  Structural basis for m 7 G recognition and 2 ′-O-methyl discrimination in capped RNAs by the innate immune receptor RIGI , 2016 .

[71]  H. Liao,et al.  Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. , 2015, The Journal of infectious diseases.

[72]  B. Seliger,et al.  Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas , 2008, Proceedings of the National Academy of Sciences.

[73]  J. Utikal,et al.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.

[74]  G. Vanham,et al.  Challenges and advances towards the rational design of mRNA vaccines. , 2013, Trends in molecular medicine.

[75]  S. Weissman,et al.  Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes. , 2008, Human gene therapy.

[76]  Xun Sun,et al.  Recent advances in mRNA vaccine delivery , 2018, Nano Research.

[77]  D. Campana,et al.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. , 2005, Blood.

[78]  D. G. Gibson,et al.  Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice , 2013, Emerging Microbes & Infections.

[79]  M. Moore,et al.  MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct , 2018, Nucleic acid therapeutics.

[80]  H. Rammensee,et al.  Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[81]  Alexander M. Seifalian,et al.  Toxicology and clinical potential of nanoparticles , 2011, Nano today.

[82]  J. Lieberman,et al.  A modular platform for targeted RNAi therapeutics , 2018, Nature Nanotechnology.

[83]  T. Schlake,et al.  mRNA mediates passive vaccination against infectious agents, toxins, and tumors , 2017, EMBO molecular medicine.

[84]  R. Deering,et al.  Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines , 2014, Expert opinion on drug delivery.

[85]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[86]  J. Martinez-Picado,et al.  Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection , 2018, AIDS.

[87]  R. Negrin,et al.  NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. , 2010, Blood.

[88]  Christopher W Mount,et al.  Potent antitumor efficacy of anti-GD2 CAR T-cells in H3K27M+ diffuse midline gliomas , 2018, Nature Medicine.

[89]  Kimberly J. Hassett,et al.  Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. , 2018, Vaccine.

[90]  B. Sullenger,et al.  From the RNA world to the clinic , 2016, Science.

[91]  Castle Raley,et al.  Targeted Gene Addition to a Safe Harbor locus in human CD34+ Hematopoietic Stem Cells for Correction of X-linked Chronic Granulomatous Disease , 2016, Nature Biotechnology.

[92]  F. Jiang,et al.  Structural basis for m7G recognition and 2′-O-methyl discrimination in capped RNAs by the innate immune receptor RIG-I , 2016, Proceedings of the National Academy of Sciences.

[93]  D. Weissman,et al.  Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge , 2017, Nature Communications.

[94]  J. Rosenecker,et al.  Expression of therapeutic proteins after delivery of chemically modified mRNA in mice , 2011, Nature Biotechnology.

[95]  Jonathan L. Kirschman,et al.  Unifying in vitro and in vivo IVT mRNA expression discrepancies in skeletal muscle via mechanotransduction. , 2018, Biomaterials.

[96]  D. Torigian,et al.  Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. , 2018, Gastroenterology.

[97]  Xiuli Wang,et al.  Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. , 2016, The New England journal of medicine.

[98]  E. Rebar,et al.  Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates. , 2016, Blood.

[99]  R. Gottardo,et al.  Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial , 2017, The Lancet.

[100]  S. Heimfeld,et al.  Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.

[101]  Mark W. Tibbitt,et al.  Synthesis and Biological Evaluation of Ionizable Lipid Materials for the In Vivo Delivery of Messenger RNA to B Lymphocytes , 2017, Advanced materials.